Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care

Abstract

The study objective was to determine whether switching patients from morphine to transdermal fentanyl resulted in a reduction of morphine-associated side effects, and an improvement in cognitive function and patients' well being while maintaining adequate pain and symptom control. Nineteen patients aged 42– 86 with terminal cancer, maintained on morphine for pain and distressed as a result of morphine toxicity, were given the dose of fentanyl corresponding to their current morphine dose. Pain control was then maintained (mostly fentanyl 50– 100 μg/h) over the 14-day study period. Throughout the study, patients' global assessment of well being (primary efficacy variable) was statistically significantly improved. Sleepiness and drowsiness were significantly less of a problem. There was a trend towards improvement in attention span/ concentration, and in the power and quality of concentration. Cognitive function tests also revealed a significant improvement in working (short term) and speed of memory although not in secondary (long term) memory. Patients did not experience hallucinations or delusions and there was no change in levels of anxiety or depression (Hospital Anxiety Depression Scale). The incidence of dizziness was significantly reduced, and there was a nonsignificant decrease in number of patients who suffered myoclonus and in the severity of this condition over the 14 days. The investigator's overall impression of treatment with transdermal fentanyl was ‘fair’, which was not in agreement with the positive impression expressed by patients (score 74, range: 0 worst, 100 best). Further work is required to determine if the improvement in patients' well being and cognitive function is achieved in larger study populations.

Keywords

cognitive function morphine opioid switching palliative care toxicity transdermal fentanyl

Get full access to this article

View all access options for this article.

References

Foley K . The treatment of cancer pain. N Engl J Med 1985; 313: 84–95.

Mercadante S . World Health Organisation guidelines: problem areas in cancer pain management. Cancer Control 1999; 6: 191–197.

Hanks G , Cherny N . Opioid analgesic therapy. In Doyle D , Hanks GWC , MacDonald N eds. Oxford textbook of palliative medicine, second edition. Oxford University Press, 1999: 331–355.

Fishbain DA , Rosomoff HL , Steele Rosomoff R . Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 1992; 8: 77–85.

Scholes C , Trotman I . The theoretical basis of opioid rotation. CME Bull Palliative Med 1: 13–15.

Mercandante S . Opioid rotation for cancer pain. Cancer 1999; 86: 1856–1866.

de Stoutz N , Bruera E , Suarez-Almazor M . Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378–384.

Bruera E , Franco J , Maltoni M , et al. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995; 10: 287–291.

Bruera E , Pereira J , Watanabe S , et al. Opioid rotation in patients with cancer pain. Cancer 1996; 78: 852–857.

10.

Bruera E , Schoeller T , Montejo G . Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 1992; 48: 397–399.

11.

Vigano A , Fan D , Bruera E . Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996; 67: 115–119.

12.

Maddocks I , Somogyi A , Abbott F , Hayball P , Parker D . Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996; 12: 182–189.

13.

World Health Organisation . Cancer pain relief and palliative care. Geneva, Switzerland, 1990.

14.

Zech DFJ , Grond SUA , Lynch J , et al. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992; 50: 293–301.

15.

Ahmedzai S , Allan E , Fallon M , et al. Transdermal fentanyl in cancer pain. J Drug Dev 1994; 6: 93–97.

16.

Ahmedzai S , Brooks D . Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage 1997; 13: 254–261.

17.

Daut RL , Cleeland CS , Flannery RC . Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other disease. Pain 1983; 17: 197–210.

18.

Johns MW . A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540–545.

19.

Hanks GW , O'Neill WM , Simpson P , et al. The cognitive and psychomotor effects of opioid analgesics. Eur J Clin Pharmacol 1995; 48: 455–460.

20.

Regnard CFB , Tempest S . A guide to symptom relief in advanced disease, fourth edition. Hochland and Hochland, 1998: 97–98.

21.

Bruera E , Miller L , McCallion J , et al. Cognitive failure in patients with cancer: a prospective study. J Pain Symptom Manage 1992; 7: 192–195.

22.

Leipzig RM , Goodman H , Gray G , et al. Reversible narcotic-associated mental status impairment in patients with metastatic cancer. Pharmacology 1987; 35: 47–54.

23.

Stiefel F , Fainsinger R , Bruera E . Acute confusional states in patients with advanced cancer. J Pain Symptom Manage 1992; 7: 94–98.

24.

Zacny JP , Lichtor JL , Flemming D , Coalson DW , Thompson WK . A dose–response analysis of the subjective, psychomotor and physiological effects of intra-venous morphine in healthy volunteers. J Pharmacol Exp Ther 1994; 268: 1– 9.

25.

Zacny JP , Lichtor JL , Thapar P , et al. Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther 1994; 270: 579–589.

26.

Clemons MJ , Regard C , Appleton T . Alertness, cognition and morphine in patients with advanced cancer. Cancer Treat Rev 1996; 22: 451–468.

27.

Jeal W , Benfield P . Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109–138.

28.

Korte W , de Stoutz N , Morant R . Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 1996; 11: 139–146.

29.

Miser AW , Narang PK , Dorhage JA , et al. Transdermal fentanyl for pain control in patients with cancer. Pain 1989; 37: 15–21.

30.

Donner B , Zenz M , Tryba M , Strumpf M . Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996; 64: 527–534.

31.

Radbruch L , Sabatowski R , Loick G , et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14: 111–119.